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BACKGROUND: Long-term data on the clinical follow-up and the treatment effectiveness of Wilson’s disease are
limited because of the low disease frequency. This study evaluated a retrospective cohort of Wilson’s disease
patients from southern Brazil during a 40-year follow-up period.
METHODS: Thirty-six Wilson’s disease patients, diagnosed from 1971 to 2010, were retrospectively evaluated
according to their clinical presentation, epidemiological and social features, response to therapy and outcome.
RESULTS: Examining the patients’ continental origins showed that 74.5% had a European ancestor. The mean age at
the initial symptom presentation was 23.3 ¡ 9.3 years, with a delay of 27.5 ¡ 41.9 months until definitive diagnosis.
At presentation, hepatic symptoms were predominant (38.9%), followed by mixed symptoms (hepatic and
neuropsychiatric) (30.6%) and neuropsychiatric symptoms (25%). Kayser-Fleischer rings were identified in 55.6% of
patients, with a higher frequency among those patients with neuropsychiatric symptoms (77.8%). Eighteen patients
developed neuropsychiatric features, most commonly cerebellar syndrome. Neuroradiological imaging abnormal-
ities were observed in 72.2% of these patients. Chronic liver disease was detected in 68% of the patients with
hepatic symptoms. 94.2% of all the patients were treated with D-penicillamine for a mean time of 129.9 ¡ 108.3
months. Other treatments included zinc salts, combined therapy and liver transplantation. After initiating therapy,
78.8% of the patients had a stable or improved outcome, and the overall survival rate was 90.1%.
CONCLUSION: This study is the first retrospective description of a population of Wilson’s disease patients of mainly
European continental origin who live in southern Brazil. Wilson’s disease is treatable if correctly diagnosed, and an
adequate quality of life can be achieved, resulting in a long overall survival.
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INTRODUCTION
Wilson’s disease (WD) is an autosomal recessive inherited
disorder of copper metabolism that leads to the accumula-
tion of this metal in different organs and tissues. Hepatic
and neurological symptoms are the main clinical features of
the disease.
In 1912, Wilson first described this disorder as a familial
disorder associated with neurologic symptoms and cirrho-
sis.
1 In 1956, Walshe first treated patients with the chelating
agent D-penicillamine.
2
The worldwide prevalence rate ranges from 10 to 30 cases
per million, with increased rates in areas of consanguinity
among parents.
3 The heterozygote carrier rate is 1 case per
100 persons, corresponding to a gene frequency varying
between 0.3% and 0.7%.
4
In WD, the processes of incorporating copper into
ceruloplasmin and excreting excess copper into bile are
impaired. The transport of copper by the copper-transport-
ing P-type ATPase is defective secondary to one of several
mutations in the ATP7B gene, which is localized in
chromosome arm 13q.
5-7 This illness involves the loss of
the ability to export copper from the liver into the bile and to
incorporate copper into hepatic ceruloplasmin. As a conse-
quence, copper accumulates in the liver, brain, kidneys and
corneas.
The gene for WD is a cation-transporting P-type ATPase
with 14 domains: 6 copper-binding domains, 4 transmem-
brane domains, 1 phosphatase domain, 1 transduction
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411domain, 1 phosphorylation domain, and 1 adenosine
triphosphate (ATP)-binding domain. About 24.6% of all
mutations involve the ATP-binding domain.
5
Patients with WD usually present with liver disease
between the first and second decades of life, whereas
neurological and psychiatric symptoms develop later.
10 The
diagnosis is confirmed by the measurements of serum
ceruloplasmin, urinary copper excretion, and hepatic
copper content, as well as the detection of Kayser-
Fleischer rings.
9 It is important to diagnose Wilson’s disease
early, before severe damage occurs. Some researchers
estimate that at least half of Wilson’s disease patients are
never diagnosed and die because of the untreated disease.
10
The aim of this retrospective report is to analyze the
clinical presentation, epidemiological and social features,
the disease course and the response to therapy in a cohort of
WD patients.
PATIENTS AND METHODS
Thirty-six patients with WD who were diagnosed from
1971 to 2010 and followed at the Departments of Neurology
and Hepatology of a tertiary academic center in southern
Brazil were reviewed. Clinical, biochemical, histological,
radiological, epidemiological and social data were extracted
from patient files and telephone contact.
The diagnosis of WD was based on clinical presentation,
familial history, Kayser-Fleischer rings detected by slit
lamp, low serum ceruloplasmin, abnormally high 24-h
urinary copper excretion, liver biopsy, a genetic test and/
or response to a D-penicillamine provocative test. Because
this cohort was retrospective, a diagnostic pattern could not
be determined for the whole group, although all 36 patients
were highly likely to be diagnosed with WD.
Patients were classified according to their age, sex, family
history and record of consanguinity among parents.
Whenever available, the patients’ continental origin was
obtained based on their knowledge of their furthest
ancestral countries of origin. This information was later
classified as being purely European or a mixed continental
origin of Europe and America. Patients with the mixed
continental origin were investigated to determine the
presence of a native indigenous ancestor.
Symptoms of initial presentation were classified into four
major groups: exclusively hepatic symptoms, exclusively
neuropsychiatric symptoms, hepatic and neuropsychiatric
symptoms (mixed presentation) and asymptomatic indivi-
duals. In addition, patients were evaluated according to the
clinical, radiological and histological investigations during
the follow-up period.
The age at initial symptoms presentation was determined.
The time between the initial symptoms and the definitive
diagnosis was calculated in months for each patient.
Patients with liver disease were classified with chronic
hepatopathy with or without portal hypertension, the
presence of cirrhosis and the Child-Pugh classification for
cirrhosis.
11 A liver biopsy was performed, when indicated,
to elucidate diagnosis. Patients with neuropsychiatric
disease were classified according to their clinical examina-
tion and radiological data.
Among patients who used D-penicillamine, the period of
treatment was calculated in months. Response to therapy
was determined based on clinical, laboratory, histological
and radiological data.
Epidemiological and social features were determined
based on the patients’ degree of instruction, marital status,
work skills and reproductive history.
A written informed consent form, approved by the local
ethic committee, was used for this study. All data are
presented as means and standard deviations. Statistical
analysis was performed using Student’s t-test and Fisher’s
exact test. A p value less than 0.05 was defined as
statistically significant.
RESULTS
Baseline Characteristics
This cohort consisted of 36 WD patients, 16 male (44.4%)
and 20 female (56.6%), with a mean age of 34.6 ¡ 10.8 (12–
63) years. Family history was obtained for 16 (44.4%)
patients, and only two individuals described a history of
consanguinity among parents (5.5%).
Data about the patients’ continental origins was available
for 31 patients (86.2%). All the original countries from their
oldest known ancestors were analyzed and included 16
(44.4%) patients from Italy, 8 (22.2%) patients from Poland,
8 (22.2%) patients from Brazil, 7 (19.4%) patients from
Portugal, 5 (13.8%) patients from Germany, 3 (8.3%) patients
from Spain, 3 (8.3%) patients from Switzerland, 2 (5.6%)
patients from Ukraine, 1 (2.7%) patient from Russia and 1
(2.7%) patient from Ireland. This cohort presented a particu-
larly high predominance of an exclusively European
continental origin (n=23, 74.5%). Eight (25.8%) subjects
reported a mixed continental origin, with ancestors from
Europe and America. Among these mixed continental origin
patients, 3 (37.5%) subjects identified the presence of a
native indigenous ancestor.
The mean age at the initial symptom presentation was
23.2 ¡ 9.3 (10–41) years. The time between the first clinical
symptom and the definitive diagnosis was 27.5 ¡ 41.9 (1–
194) months.
Clinical Features
At presentation, 9 patients (25%) showed exclusively
neuropsychiatric symptoms, 14 (38.9%) patients exclusively
hepatic symptoms, 11 (30.6%) patients demonstrated both
hepatic and neuropsychiatric features (mixed presentation)
and 2 (5.5%) patients were asymptomatic. The diagnosis
among asymptomatic subjects was achieved through
genetic family screening.
The age at the initial symptom was not different among
the group of patients with exclusively neuropsychiatric
symptoms (21.1 ¡ 8.9 years), exclusively hepatic symptoms
(20.6 ¡ 7.2 years) or a mixed presentation (26.8 ¡ 9 years).
The mean time between the first clinical symptom and the
definitive diagnosis was 18.5 ¡ 12.4 (1–36) months for
patients with exclusively neuropsychiatric symptoms, 6.7 ¡
5.8 (1–16) months for patients with exclusively hepatic
symptoms and 51 ¡ 59.6 (1–194) months for patients with a
mixed presentation. A statistical analysis showed a sig-
nificant difference in the time required for the definitive
diagnosis between patients with exclusively neuropsychia-
tric symptoms and exclusively hepatic symptoms (p =
0.02). There was no reduction in the time lag from the
appearance of the first symptoms to the diagnosis in the
more recent decades of this 40-year period of analysis.
The major findings of the initial clinical-laboratorial eva-
luation are presented in table 1. The patients were further
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412assessed according to their physical exam, neuroradiologi-
cal imaging and histological findings.
Kayser-Fleischer Ring Analysis
Kayser-Fleischer rings were identified in 20 (55.6%) of the
36 subjects. These rings were most prevalent in patients
with exclusively neuropsychiatric symptoms at presentation
(77.8%), followed by patients with the mixed disease
presentation (72.2%). Rings were least prevalent in subjects
with exclusively hepatic symptoms (35.7%). Statistical
analysis showed no significant differences when comparing
the exclusively hepatic disease group and the neuropsy-
chiatric group (p=0.08) or the mixed disease group
(p=0.11). Both asymptomatic patients did not present
Kayser-Fleischer rings.
Neuroradiological Imaging
Eighteen patients presented or developed neuropsychia-
tric features during the follow-up observation. All of them
were submitted to a neuroradiological analysis with
tomography or magnetic resonance imaging (MRI).
Thirteen (72.2%) patients showed abnormalities previously
described among WD neuropsychiatric patients. Major
findings included brain atrophy with basal ganglia hyper-
intensities. In one patient, the MRI revealed the ‘‘face of the
giant panda’’ sign that is characteristic of WD.
Liver Disease Evaluation
All 36 patients were submitted to an abdominal ultra-
sound. Chronic liver disease features were detected in 17
(68%) of the 25 patients with hepatic symptoms and only in
3 (27.2%) of the remaining subjects (p=0.03). Among the 20
patients with ultrasound abnormalities, portal hypertension
was demonstrated in 13 (65%) cases.
Sixteen patients with hepatic symptoms were submitted
to a liver biopsy, and the histological findings are described
in table 2.
Cirrhotic patients (n=15) were classified according to the
Child-Pugh Classification: 73.4% of patients were Child-
Pugh A, and 26.6% of patients were Child-Pugh B or C
(equal proportions of each group).
Treatment
Thirty-five patients were submitted to pharmacological
treatment. Initially, 33 (94.2%) subjects were treated with
D-penicillamine, and only two (5.8%) subjects were treated
with zinc acetate.
One of the patients started on zinc acetate was an
asymptomatic teenager diagnosed through genetic family
screening, and the other one was a young woman with a fast
progressive neurological disease for whom D-penicillamine
treatment could be potentially deleterious as the first choice
of therapy.
Among the group of patients who were started on D-
penicillamine, therapy had to be switched to zinc acetate in
3 (9.1%) subjects. The reasons included pregnancy (1
subject) and the development of severe Parkinsonism,
which improved after D-penicillamine treatment disconti-
nuation (1 subject). The third patient had the D-penicilla-
mine treatment stopped altogether for his own safety
because he presented a significant nonadherence to the
medication posology and poor treatment compliance.
Table 1 - Clinical-Laboratory Findings (n=36).
Neurological/Psychiatric Hepatological Ophtalmological Renal Hematological Other Findings
Tremor of extremities
(27.7%)
Cirrhosis (44.4%) Kayser-Fleischer ring
(55.6%)
Hypercalciuria
(11.1%)
Hemolytic anemia
(16.6%)
Arthralgia (5.5%)
Dysarthria (25%) Portal hypertension (30.5%) Kidney stones
(8.3%)
Thrombocytopenia
(5.5%)
Morning stiffness
(5.5%)
Cerebellar disturbances
(13.9%)
Jaundice (16.6%) Skin hyperpigmentation
(11.1%)
Dystonia (11.1%) Astheny (8.3%) Hair rarefaction (8.3%)
Parkinsonism (11.1%) Acute liver failure (11.1%) Asymptomatic (5.5%)
Others (headache/syncope)
(5.5%)
Elevated liver transaminases
(2.7%)
Psychiatric (bipolar disorder,
attention deficit disorder,
personality alterations, body
negligence, irritability,
hypersomnia) (16.6%)
High digestive hemorrhage
(5.5%)
Table 2 - Hepatic Histological Findings (n=16).
Subject Gender Age Histological Findings
1 M 26 Micronodular cirrhosis with
mononuclear cellular infiltrate
2 F 17 Postnecrotic cirrhosis
3 F 29 Mild mononuclear cellular infiltrate
4 F 21 Postnecrotic cirrhosis
5 M 22 Bridging portal fibrosis with
mononuclear cellular infiltrate
6 F 32 Micronodular cirrhosis with
mononuclear cellular infiltrate
7 M 55 Lobular hepatitis and limiting plate
mononuclear cellular infiltrate
8 M 29 Submassive hepatic necrosis
9 F 39 Chronic cholestatic hepatitis
10 M 30 Lobular hepatitis and limiting plate
mononuclear cellular infiltrate
11 M 38 Micronodular cirrhosis with
mononuclear cellular infiltrate
12 M 22 Micronodular cirrhosis with
mononuclear cellular infiltrate
13 F 27 Lobular hepatitis and limiting plate
mononuclear cellular infiltrate
14 M 33 Micronodular cirrhosis with
mononuclear cellular infiltrate
15 F 20 Massive hepatic necrosis
16 F 40 Periportal inflammation and lobular
cells cholestasis
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413During follow-up, 2 (6.1%) patients who were on D-
penicillamine therapy demonstrated disease progression
and a second drug was added to the treatment (zinc
acetate). Combination therapy stabilized disease progres-
sion in both cases but did not improve the symptoms.
Liver transplantation was indicated in one patient who
developed chronic progressive liver failure after 8 years of
D-penicillamine treatment.
One asymptomatic subject diagnosed through genetic
family screening remained without therapy and was
receiving periodic clinical-radiological follow-up.
Outcomes
The mean duration of treatment with D-penicillamine
was 129.9 ¡ 108.3 (5–468) months.
At the end of the follow-up, we evaluated whether
hepatic features and neuropsychiatric signs had stabilized,
improved or worsened. Six (18.2%) patients showed signs of
improvement, and 20 (60.6%) patients remained clinically
stable. Another six (18.2%) subjects presented a progressive
disease with worsening of symptoms (4 patients with
neurological disease and 2 patients with hepatic disease),
although one of them had a significant alcoholic addiction
and therefore poor treatment compliance. Three (9.1%)
patients died, one of whom died due to the development of
cancer (leukemia). Patients with chronic liver disease were
periodically screened for hepatocellular carcinoma, and
none of them developed it. The patient who had the liver
transplantation has remained clinically stable for 4 years
after the procedure and is still receiving follow up. The
overall survival rate was of 90.1% at the end of the follow-
up period.
Epidemiological and Social Features
Fourteen of the 26 subjects who were older than 25 years
were married, and 8 (57.2%) of them had children. After the
diagnosis, one female patient with predominantly neurolo-
gical features had 8 miscarriages, and 2 others also had
miscarriages before a successful pregnancy. In one patient,
treatment with D-penicillamine was switched to zinc acetate
during pregnancy, and no abnormalities were observed
during the pregnancy or in the offspring.
Among the 33 patients older than 18 years, 14 (38.9%) have
work skills and are employed, and 2 subjects have bachelor’s
degrees. Most of the subjects are underemployed. Two
(6.1%) of the working-age subjects are retired because of
limitations associated with WD. Three (8.3%) patients are
younger than18 years,andall of them are studying properly.
DISCUSSION
The results of the present study describe a historical
cohort of 36 WD patients with an equal distribution between
the genders. The mean age at diagnosis is similar to the ones
described previously by other authors.
12-14 There are,
however, reports of onset of symptoms on the extremes of
age.
15,16 Thus, WD must be considered at all ages.
Characteristically, our study population is composed
mainly of subjects with a European continental origin.
This distribution reflects the European colonization of
southern Brazil during the nineteenth century, particularly
by Germans, Poles and Italians.
17 This distribution differs
from the rest of the country, where a mixed continental
origin is more common, mostly because of a high prevalence
of native indigenous and African ancestors.
18
Recent literature shows a progressive reduction of the gap
between the initial symptom and the definitive diagnosis.
19
On the contrary, the mean gap in this study (27.5 months)
still demonstrates a significantly long period of time for the
correct diagnosis of WD to be established, even in the more
recent decades of this 40-year analysis. Similar results (25.3
months) were observed in another study, and the authors
state that because there are several different clinical presen-
tations of WD, the analysis of the diagnostic findings under-
scores the difficulties in diagnosing WD.
20 The delay in
the diagnosis is regrettable because the longer the disease
progresses without treatment, the more likely that the
damage to the liver and/or brain will be permanent.
The time lag from the appearance of the first symptoms to
the diagnosis showed a great amount of variation, from 1 to
194 months. The neurological presentation was associated
with a statistically significantly longer period of time from
the onset of symptoms to the diagnosis than the hepatic
presentation. Although there is not a consensus currently,
several literature reports corroborate this finding.
10,20,21
Although the pathogenic defect of WD is located in the
hepatobiliary system, the consequences of copper accumu-
lation may be detected in several organs and tissues.
8 The
most important clinical manifestations of copper overload
are hepatic (45%–58%), neuropsychiatric (30%–33%) or a
combination of both.
20,22,23 Clinical manifestations among
the 36 cohort patients are similar to these proportions.
Usually, hepatic disease occurs between the first and
second decades of life, whereas neurological symptoms
develop later.
10 In fact, the study conducted by Merle et al.
in 2007 demonstrated that patients with mainly hepatic
symptoms showed an overall earlier onset of symptoms
(mean age: 15.5 years) than patients with predominantly
neurological symptoms (mean age: 20.2 years).
20 Our
results, probably restricted by the small number of subjects,
show no differences in the age of the onset of the symptoms
among patients with exclusively neuropsychiatric disease,
exclusively hepatic disease or mixed presentation.
Most authors agree that the majority of WD patients have
signs of hepatic disease, and some authors believe that all
patients have some degree of hepatic dysfunction.
22 In fact,
the manifestations of hepatic disease may vary widely, from
nonspecific hepatomegaly to severe forms of liver failure.
21
As demonstrated in this study, the development of progres-
sive chronic liver disease occurs most frequently. In general,
liver histological analysis results in nonspecific multivari-
able features common to other chronic liver diseases.
24 The
data from the present study corroborate these findings.
Kayser-Fleischer rings were detected in 55.6% of the
subjects, with a higher frequency among those patients with
exclusively neuropsychiatric symptoms (77.8%). Previous
reports described the presence of the Kayser-Fleischer rings
in WD patients with a frequency range of 66.3% to
95%.
20,25,26 In theory, this sign is observed in virtually all
patients with neurological disease, although studies have
reported lower frequencies, such as 85%.
20 The relatively
low frequency of Kayser-Fleischer rings observed among
our patients with neuropsychiatric symptoms may be
underestimated because of the variation in the slit lamp
exam’s quality during the 40-year period that we retro-
spectively analyzed but may also underscore the difficulties
in diagnosing WD.
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414At presentation, neuropsychiatric signs were the exclu-
sive features in 25% of the WD patients. About 40%–50% of
patients with WD have neurological or behavioral symp-
toms at the time of diagnosis.
10 Advances in neuroimaging
have improved our understanding of the pathophysiology
of WD. Besides the ‘‘face of giant panda’’ sign, hyperinten-
sities in tectal plate and the central pons as well as the
simultaneous involvement of the basal ganglia, thalamus
and brainstem are almost pathognomonic of WD.
28 MRI
changes tend to be more severe and widespread in patients
with neurological disease,
29 with a strong correlation with
disease severity scores.
30
Lifelong treatment is required for WD. The best thera-
peutic approach remains controversial, and there is no
universally accepted regimen.
10 In this cohort, we describe
the analysis of more than 10 years of follow up during WD
treatment.
The majority of our patients were treated with D-
penicillamine. The choice for zinc salts was made in
asymptomatic patients, during pregnancy or to potentially
avoid further acute neurological deterioration. Although
controversial, recent data have suggested that D-penicilla-
mine should not be the drug of choice for patients with
neurological features because of the drug’s potential to
induce the development or worsening of neurological
symptoms.
20 When signs of treatment failure occurred, a
second drug was added to the therapy. Of note, none of the
patients in this cohort were on trientine treatment because
trientine treatment is not available through Brazilian public
health assistance.
With medical treatment and liver transplants, 72.2% of the
patients stabilized or improved. The study of Merle et al.
described similar results, and 76.1% of their analyzed
patients experienced a stable or improved course of
disease
20, highlighting not only the importance of early
diagnosis but also compliance to therapy.
The development of new symptoms or the progression of
preexisting symptoms was more often recorded for patients
with neuropsychiatric symptoms (4/6 subjects) than for
patients with hepatic symptoms (2/6 subjects). Not unex-
pectedly, the deterioration of the disease in its various forms
was detected almost invariably in noncompliant patients.
Clinical deterioration, despite the appropriate treatment, is
highly dependent on the compliance of how early therapy
is started and on the individual’s response to therapy.
31
Three patients died during follow-up; one patient died
because of the development of a blood malignancy
(leukemia). Despite the description of a common mechan-
ism of copper accumulation in WD and cancer, hepatocel-
lular carcinoma and other tumors of the liver are extremely
rare in patients with WD. Although the causes are
dramatically different, cancer shares a similar defect in
copper homeostasis with WD; therefore, treatments like
copper chelation therapy have been used against cancer.
32
There are only a few reports addressing fertility and the
outcome of pregnancy in WD.
33,34 As observed here,
recurrent miscarriages are common, especially in women
with untreated WD. However, successful pregnancies and
full-term delivery may occur.
34 Data on quality of life and
social features are scarce in the literature.
35 Because WD has
a long overall survival with adequate treatment, these
features need to be analyzed. The present results demon-
strate that besides a positive life expectancy, WD patients
can achieve an adequate pattern of quality of life, work
skills and social inclusion.
To conclude, this study is the first clinical description of a
cohort of WD patients with mainly European continental
origin who live in southern Brazil. Therefore, the pheno-
typic features detailed in this study may contribute to our
knowledge about the regional distribution of the disease in a
country with such a highly multiracial population. As
demonstrated here, WD is treatable if correctly diagnosed,
and an adequate quality of life can be achieved with
treatment, resulting in a long overall survival. Because there
is no consensus therapy, treatment should be individua-
lized, and careful follow-up is mandatory.
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